A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full trial results for humans are expected later in 2025. Results from the Phase II COURAGE trial show that Regeneron’s combination of semaglutide plus trevogrumab significantly enhanced fat loss while preserving lean muscle mass in patients with obesity. ...
Websim.ai is an AI-powered platform that allows users to generate and explore a simulated version of the internet. It uses advanced AI models like Claude 3.5 Sonnet and GPT-4o to create interactive websites, visualizations, and functional code in response to user prompts. Users can sign in with their Google or Discord accounts and input prompts ... Read more
Comments
Post a Comment